Keyword: UC San Francisco
Two research groups have uncovered clues to immuno-oncology drug resistance, offering insight that could lead to new treatment strategies.
A UCSF team found that Type 1 diabetes starts with "secretory senescence," a process whereby DNA damage causes beta cells to stop working properly.
The week’s biotech news included an eFFECTOR drug that slows liver cancer in mice and insight into age-related muscle decline.
UCSF researchers have modified CRISPR gene editing to increase the activity of genes that create the feeling of being full.
Combining EGFR inhibitors with drugs targeting Aurora kinase A killed cancer cells permanently, a University of California, San Francisco, team found.
Livongo and the University of California, San Francisco, launched a randomized, controlled trial that will recruit 300 adults with Type 2 diabetes.
A UCSF spinoff is working with GlaxoSmithKline to develop a drug to target a common mutation in glioblastoma.
A new electroporation-based CRISPR-Cas9 method could improve gene editing for CAR-T and other cell therapies.
UC San Francisco scientists used a process called synNotch signaling to prompt individual cells to form tissue structures.
UCSF researchers are figuring out how to set prostate cancer cells on a path to self-destruction by interfering with a process that controls protein synthesis.